Vijaya Diagnostic Centre Ltd. · NSE:VIJAYA
Vijaya Diagnostic Centre — Q4 FY22 Earnings Presentation
37 slides from Vijaya Diagnostic Centre's earnings presentation
Slide 1: Vijaya Diagnostic Centre Limited Investor Presentation Q4 & FY22
Vijaya Diagnostic Centre Limited Investor Presentation Q4 & FY22
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 3: Q4 & FY22 Financial Performance
Q4 & FY22 Financial Performance
Slide 4: Q4 & FY22 – Performance Snapshot
Q4 & FY22 – Performance Snapshot Operational & Financial Highlights – Q4 FY22 Operational & Financial Highlights – FY22 2.45 Mn 9.32 Mn Tests Tests INR 1,162.0 Mn INR 4,623.7 Mn Revenue Revenue 0.96 Mn 3.62 Mn Footfalls Footfalls INR 478.6 Mn INR 2,036.9 Mn 95 EBIDTA 95 EBIDTA Centres Centres (opene
Slide 5: Key Operational Highlights (1/2)
Key Operational Highlights (1/2) Annual Quarterly Tests Performed (# in Million) 3% Y-o-Y 9.32 2.45 2.38 7.91 2.32 6.99 7.09 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 Footfalls (# in Million) 8% Y-o-Y 3.62 0.96 0.89 0.85 2.79 2.63 2.38 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 5
Slide 6: Key Operational Highlights (2/2)
Key Operational Highlights (2/2) Annual Quarterly Revenue per Test (INR) 531 470 477 474 496 419 428 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 Revenue per Footfall (INR) 1,265 1,303 1,212 1,431 1,228 1,214 1,276 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 6
Slide 7: Revenue – COVID, COVID Allied and Non-COVID
Revenue – COVID, COVID Allied and Non-COVID (INR Mn) Annual Quarterly Non-COVID Revenue -2% Y-o-Y 3,930 3,388 1,004 1,022 983 3,124 2,926 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 COVID & COVID Allied Revenue* % of Revenue 17.1% 15.0% 10.4% 7.8% 15.4% 694 179 643 21 108 170 117 20 86 10 158 535 524 9
Slide 8: Key Financial Highlights
Key Financial Highlights (INR Mn) Annual Quarterly Revenue from Operations 4% Y-o-Y 4,624 1,120 1,162 1,108 3,767 3,388 2,926 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 EBITDA & EBITDA Margin (%) 37.0% 39.1% 44.1% 44.1% 48.6% 43.2% 41.2% 2,037 544 478 479 1,660 1,326 1,081 FY19 FY20 FY21 FY22 Q4FY21 Q
Slide 9: Consolidated Profit & Loss Account – Q4 & FY22
Consolidated Profit & Loss Account – Q4 & FY22 (INR Mn) Particulars Q4FY22 Q4FY21 Y-o-Y Q3FY22 Q-o-Q FY22 FY21 Y-o-Y Revenue from operations 1,162.0 1,120.1 4% 1,107.8 5% 4,623.7 3,767.5 23% Cost of materials consumed 178.8 162.6 10% 163.0 10% 715.0 570.9 25% Employee benefits expense 192.0 151.7 27
Slide 10: Company Overview
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Company Overview The Pioneers in Diagnostic Medicare.
Slide 11: Vijaya at a Glance
Vijaya at a Glance Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 95 state-of-the-art centres spread across 16 cities 40+ 95 Mission Years of Experience Centres Quality Experience in delivering Quality Diagnostic Service State-of-the-art Facilities wi
Slide 12: Our Journey
Our Journey Awarded Brand of the year in diagnostic One of the earliest private diagnostic Recognized as one of the Best Imaging services by The CEO Magazine and service providers to be approved for Vijaya Diagnostic Centre centres in Hyderabad by The Week Telangana Healthcare Leadership award COVID
Slide 13: At the Forefront of Introducing New Technologies
At the Forefront of Introducing New Technologies Ultrasound & Nuclear Medicine Fourth Generation 1981 Echocardiography 1986 1993 CT Scan 1994 Offer Mammography facility Hawkeye Gamma Automated Microbiology Real Time RT-PCR Assays 2006 2003 Culture 2000 1999 Bone Densitometry Camera with SPECT & Flow
Slide 14: Our Pillars of Strength
Our Pillars of Strength 1 One of the leading players in India’s high growth diagnostics market 2 Integrated diagnostics provider offering one-stop solution 3 High brand recall driving customer stickiness 4 Robust technical capabilities and state-of-the-art technology 5 Experienced Board and strong m
Slide 15: Indian Diagnostics Market expected to Grow at a Healthy Trajectory
Indian Diagnostics Market expected to Grow at a Healthy Trajectory Indian Diagnostics Market Segment-wise breakup of Indian Diagnostic Market (INR Bn) Radiology Pathology 980 980 +13% +13% FY23E CAGR CAGR 275 - 285 43% - 44% 684 684 FY20 +13% - 14% 190 - 195 CAGR 43% 472 472 +14% CAGR South India 41
Slide 16: One of the leading players in India’s high growth diagnostics market
One of the leading players in India’s high growth diagnostics market Telangana and Andhra Pradesh Market Size Vijaya’s Core Geographies Telangana and Andhra (INR Bn) Dominant Position in Pradesh (44 - 46% of South Telangana & India) Andhra Pradesh +14% 120 -130 Karimnagar CAGR Mancherial Nizamabad 8
Slide 17: Integrated Diagnostic service provider with extensive network…
Integrated Diagnostic service provider with extensive network… National Reference Lab Vijaya Diagnostic Centre Flagship Centre #1 #1 Reference Lab Customers Hubs #23 Samples #11 Customer (Walk-in) Home Collection B2B Hospitals & Labs Sample Flow Patient Flow Diagnostic Centres / Spokes #71 Flagship
Slide 18: …offering One-Stop Solutions for Pathology & Radiology
…offering One-Stop Solutions for Pathology & Radiology Complete Range of Diagnostic Services under One Roof Comprehensive and high quality integrated diagnostic services through our operational network 18
Slide 19: High brand recall driving customer stickiness
High brand recall driving customer stickiness Customer Centric Approach Quality Diagnostic Services B2C Revenue 90% 93% 92% 94% Higher brand recall FY19 FY20 FY21 FY22 High share of walk-in customers Operational Metrics (INR) Sticky individual customer 1,431 1,228 1,214 1,276 “For excellence in Qual
Slide 20: Robust Technical Capabilities with State-of-the-art IT Infrastructure
Robust Technical Capabilities with State-of-the-art IT Infrastructure 5 Advanced Software to Manage Clinical Data 17 CT Machines PET CT / Gamma machines 20 200+ Fully Integrated Radiology Advance Laboratory MRI Machines Radiologists, Lab Doctors & Information Systems (RIS) and Information Management
Slide 21: Experienced Board of Directors
Experienced Board of Directors Dr. S Surendranath Reddy - Executive Chairman Dr. D Nageshwar Reddy - Non-executive, Independent Director Founder of Vijaya with 40+ years of experience in building Vijaya as South India’s largest integrated diagnostic chain Chairman of Asian Institute of Gastroent
Slide 22: Strong Management Team
Strong Management Team Dr. S. Surendranath Reddy Mr. Sunil Chandra Kondapally Ms. Suprita Reddy Mr. Narasimha Raju K.A Ms. Anusha Kanumuru Executive Chairman Executive Director Chief Executive Officer Chief Financial Officer Company Secretary & Compliance Officer 40+ years of experience in With
Slide 23: Awards & Accolades
Awards & Accolades One of the Best Healthcare Indo Global Award for Company of the Year - Leading Diagnostic Chain of the India’s Greatest Leaders 2020-21 Brands 2021 Healthcare Excellence Healthcare Year Ms. Suprita Reddy - CEO 2021 2021 2021 2021 2021 Presented by Presented by Presented by Present
Slide 24: Shareholding Pattern
Shareholding Pattern Others Shareholding Pattern as of 31st March 2022 FII’s 4.0% Category % Holding Fidelity Group#^ 9.1% 28.1% Wasatch Advisors^ 7.9% Promoter & Promoter Axis Mutual Fund^ 6.6% 54.8% group Aberdeen Standard Investments^ 5.8% 13.1% Nippon Life India Asset Management^ 2.2% Aditya Bir
Slide 25: Strategy Going Forward
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Strategy Going Forward
Slide 26: Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh
Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh Leveraging Existing Presence Given under-penetration of diagnostic market, we will continue to focus on Opening additional diagnostic centres through owned & franchisee model Mancherial Nizamabad Karimnagar Expanding network through s
Slide 27: Expand in Adjacent Geographies & East India
Expand in Adjacent Geographies & East India Network (FY22) East India Strategy Expand presence in East India given growing demand Replicate our successful hub and spokes model in East India Established a hub in Kolkata and plan is to set up additional diagnostic centres South India Strategy ar
Slide 28: Continued Focus on Providing Customer Centric Services and Offerings
Continued Focus on Providing Customer Centric Services and Offerings Preventive and Wellness Testing to Boost Demand for Diagnostics FY20E Industry Size FY23P CAGR: ~20% 101-108 61-68 Rest of the Wellness & Rest of the Wellness & market Preventive market Preventive 90% 9% - 10% 89% 11% FY20 FY23 Key
Slide 29: Financial & Operational Highlights
Financial & Operational Highlights
Slide 30: Robust Operational Metrics
Robust Operational Metrics Diagnostic Centre (Nos) Footfalls (Mn) Tests Performed (Mn) 95 3.62 9.32 80 7.91 73 2.79 6.99 7.09 61 2.63 2.38 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Test per Footfall (Nos) Revenue per Test (INR) Revenue per Footfall (INR) Impact of COVID-19 531 496
Slide 31: Consistent Financial Performance
Consistent Financial Performance (INR Mn) Revenue EBIDTA PAT CAGR:16% 4,624 CAGR:24% 1,097 2,037 CAGR:34% 3,767 3,388 1,660 845 2,926 1,326 625 1,081 459 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 EBIDTA Margin (%) PAT Margin (%) 710 bps 800 bps 22.4% 23.7% 44.1% 44.1% 18.5% 15.7% 3
Slide 32: Sustainable Cash Generation & Increasing Return Ratios
Sustainable Cash Generation & Increasing Return Ratios Cash & Cash Equivalents CFO / EBIDTA (%) (INR Mn) 2,467 84% 80% 2,277 78% 77% 1,729 1,215 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 RoCE Pre-Cash (%) RoE (%) 43% 23% 38% 23% 23% 33% 22% 30% FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 ROCE (Pre-cash):
Slide 33: Annexure
VIJAYA fc 5) DIAGNOSTIC [WISAYA] CENTRE Annexure The Pioneers in Diagnostic Medicare.
Slide 34: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account (INR Mn) Particulars FY22 FY21 FY20 FY19 Revenue from operations 4,624 3,767 3,388 2,926 Cost of materials consumed 715 571 439 405 Employee benefits expense 707 574 624 539 Other expenses 1,165 962 999 901 EBITDA 2,037 1,660 1,326 1,081 EBITDA % 44.1% 44.1% 39.1%
Slide 35: Consolidated Balance Sheet
Consolidated Balance Sheet (INR Mn) Assets Mar-22 Mar-21 Mar-20 Mar-19 EQUITY AND LIABILITIES Mar-22 Mar-21 Mar-20 Mar-19 NON-CURRENT ASSETS 4,436 3,022 2,959 2,689 EQUITY 4,695 3,592 2,741 2,069 Property, plant and equipment 1,966 1,358 1,398 1,437 Equity share capital 102 45 45 45 Capital work-in-
Slide 36: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (INR Mn) Particulars Mar-22 Mar-21 Mar-20 Mar-19 Cash Flow from Operating Activities Profit before Tax 1,474 1,121 834 653 Adjustment for Non-Operating Items 572 534 492 431 Operating Profit before Working Capital Changes 2,046 1,655 1,326 1,084 Changes in Working Ca
Slide 37: THANK YOU
THANK YOU Company Investor Relations Advisors Vijaya Diagnostic Centre Limited (VDCL) Citigate Dewe Rogerson (CDR India) Mr. Anoop Poojari / Mr. Siva Rama Raju – Head of Strategy Mr. Devrishi Singh +91 90597 00749 / +91 99485 95555 sivaramaraju.v@vijayadiagnostic.in Tel: +91 98330 90434 / ir@vijayad
Vijaya Diagnostic Centre — Q4 FY22 Earnings Presentation on 6ix